(Q48858718)

16 February 2018

title

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. (English)

1 reference

16 February 2018

0 references

0 references

1 reference

H F Petereit

1

1 reference

16 February 2018

A Rubbert-Roth

series ordinal

2

1 reference

16 February 2018

publication date

29 October 2008

1 reference

16 February 2018

Multiple Sclerosis Journal

published in

1 reference

16 February 2018

volume

15

1 reference

16 February 2018

issue

2

1 reference

16 February 2018

page(s)

189-192

1 reference

16 February 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508098268

Crossref

reference URL

retrieved

21 January 2018

An open label study of the effects of rituximab in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1177%2F1352458508098268

Crossref

reference URL

retrieved

21 January 2018

Pharmacokinetic Behavior of Rituximab

1 reference

https://api.crossref.org/works/10.1177%2F1352458508098268

Crossref

reference URL

retrieved

21 January 2018

Identifiers

DOI

10.1177/1352458508098268

1 reference

16 February 2018

PubMed ID

18971221

1 reference

16 February 2018